Miloslav Beran

12.3k citations

106 papers · 8.5k indexed · 2 hit papers · h-index 46

Hematology top 0.05%
Genetics top 0.1%
Public Health, Environmental and Occupational Health top 0.5%
Molecular Biology top 5%
Oncology top 1%

Co-authors: Hagop M. Kantarjian Michael J. Keating Charles Koller Jörge E. Cortes Elihu H. Estey Francis J. Giles Susan O’Brien Sherry Pierce
Topics: Chronic Myeloid Leukemia Treatments (47 papers)Chronic Lymphocytic Leukemia Research (46 papers)Acute Myeloid Leukemia Research (45 papers)
Cited by: Hematology Genetics Pathology and Forensic Medicine
Journals: Nature New England Journal of Medicine Proceedings of the National Academy of Sciences
Partner nations: United States Switzerland Canada

In The Last Decade

Miloslav Beran

105 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

1997 909 citations Sergio Giralt, Elihu H. Estey et al. Blood profile →
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

2000 586 citations Hagop M. Kantarjian, Jörge E. Cortes et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Miloslav Beran

Since Specialization

Citations

This map shows the geographic impact of Miloslav Beran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miloslav Beran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miloslav Beran more than expected).

Fields of papers citing papers by Miloslav Beran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miloslav Beran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miloslav Beran. The network helps show where Miloslav Beran may publish in the future.

Co-authorship network of co-authors of Miloslav Beran

This figure shows the co-authorship network connecting the top 25 collaborators of Miloslav Beran. A scholar is included among the top collaborators of Miloslav Beran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miloslav Beran. Miloslav Beran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells 2005 ·Cancer ·Srđan Verstovšek,Mirna Golemović,Hagop M. Kantarjian,(unknown),Zeev Estrov,Paul W. Manley,Tong Sun,Ralph B. Arlinghaus,Leila Alland,Margaret Dugan,Jörge E. Cortes,Francis J. Giles,Miloslav Beran	55
2	The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) 2005 ·Leukemia Research ·Francis J. Giles,William Bellamy,Zeev Estrov,Susan O’Brien,Srđan Verstovšek,Farhad Ravandi,Miloslav Beran,Paul Bycott,Yazdi K. Pithavala,Heidi Steinfeldt,Steven D. Reich,Alan F. List,Karen Yee	38
3	Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia 2004 ·Cancer ·Hagop M. Kantarjian,Deborah A. Thomas,Susan O’Brien,Jörge E. Cortes,Francis J. Giles,Sima Jeha,Carlos E. Bueso‐Ramos,Sherry Pierce,Jianqin Shan,Charles Koller,Miloslav Beran,Michael J. Keating,Emil J. Freireich	454
4	Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation 2004 ·British Journal of Haematology ·Nada Oršolić,Francis J. Giles,Henriette Gourdeau,Mirna Golemović,Miloslav Beran,Jörge E. Cortes,Emil J. Freireich,Hagop M. Kantarjian,Srđan Verstovšek	6
5	Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia 2004 ·Bone Marrow Transplantation ·(unknown),Rima M. Saliba,Sergio Giralt,Munir Shahjahan,A Cohen,Safa Karandish,Francesco Onida,Miloslav Beran,Richard E. Champlin,M. Lima	61
6	Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein 2004 ·Cancer ·Barbara Scappini,(unknown),Francesco Onida,Clara Ricci,Vladimír Divoký,William G. Wierda,Michael Andreeff,(unknown),Kimberly Hayes,Srđan Verstovšek,Hagop M. Kantarjian,Miloslav Beran	34
7	Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase 2003 ·Leukemia Research ·Francis J. Giles,Eric J. Feldman,Gail J. Roboz,Richard A. Larson,(unknown),Jörge E. Cortes,Srđan Verstovšek,Stefan Faderl,Moshe Talpaz,Miloslav Beran,Maher Albitar,Susan O’Brien,Hagop M. Kantarjian	18
8	High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia 2001 ·Cancer ·Jörge E. Cortes,Elihu H. Estey,Susan O’Brien,Francis J. Giles,Yu Shen,Charles Koller,Miloslav Beran,Deborah A. Thomas,Michael J. Keating,Hagop M. Kantarjian	44
9	High-dose chemotherapy in high-risk myelodysplastic syndrome 2001 ·Cancer ·Miloslav Beran,Yu Shen,Hagop M. Kantarjian,Susan O’Brien,Charles Koller,Francis J. Giles,Jörge E. Cortes,Deborah A. Thomas,Stefan Faderl,(unknown),Elihu H. Estey	70
10	Complete hematologic and cytogenetic response to 2-amino-9-?-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogeneous leukemia in T-cell blastic phase 1999 ·Cancer ·Álvaro Aguayo,Jörge E. Cortes,Hagop M. Kantarjian,Miloslav Beran,Varsha Gandhi,William Plunkett,Joanne Kurtzberg,Michael J. Keating	14
11	Chronic myelogenous leukemia in nonlymphoid blastic phase 1999 ·Cancer ·Stefano Sacchi,Hagop M. Kantarjian,Susan O’Brien,Jörge E. Cortes,Mary Beth Rios,Francis J. Giles,Miloslav Beran,Charles Koller,Michael J. Keating,Moshe Talpaz	155
12	Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy 1998 ·Blood ·Michael J. Keating,Susan O’Brien,Susan Lerner,Charles Koller,Miloslav Beran,L. E. Robertson,Emil J. Freireich,Elihu H. Estey,Hagop M. Kantarjian	345
13	Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia 1997 ·Leukemia ·Stefano Sacchi,HM Kantarjian,Stephen J. O’Brien,Miloslav Beran,Charles Koller,Sherry Pierce,Steven M. Kornblau,Elihu H. Estey,MJ Keating,Moshe Talpaz	14
14	Lack of Effect of 2-Chlorodeoxyadenosine Therapy in Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine Therapy 1994 ·New England Journal of Medicine ·Susan O’Brien,Hagop M. Kantarjian,Elihu H. Estey,Charles Koller,(unknown),Miloslav Beran,Michael Andreeff,Sherry Pierce,Michael J. Keating	73
15	Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. 1993 ·Journal of Clinical Investigation ·Meir Wetzler,Moshe Talpaz,Richard A. Van Etten,(unknown),Miloslav Beran,Razelle Kurzrock	158
16	Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. 1992 ·Journal of Clinical Oncology ·H. Kantarjian,Moshe Talpaz,Dimitrios P. Kontoyiannis,(unknown),M Keating,Elihu H. Estey,Stephen O’Brien,Mary Beth Rios,Miloslav Beran,AB Deisseroth	58
17	2-Chlorodeoxyadenosine: A new anticancer agent in lymphoid malignancies 1991 ·(unknown),Razelle Kurzrock,Hagop M. Kantarjian,CA Koller,S O'Brien,Miloslav Beran,Michael J. Keating,K. B. McCredie,Emil J. Freireich	3
18	Development of a second Philadelphia (Ph1) chromosome in chronic myelogenous leukemia (CML) is characterized by a single aberrant overexpressed 8 kb c-abl transcript and the loss of the normal c-abl transcripts 1985 ·Proceedings of the American Association for Cancer Research ·Mark Blick,Björn Andersson,Miloslav Beran	1
19	Adherent cell-mediated inhibition of human leukemic myelopoiesis. 1980 ·PubMed ·Gary Spitzer,(unknown),A Zander,Miloslav Beran,Dicke Ka,Sharon Tindle,Steven J. Siegel	3
20	Preoperative Facial Paralysis in Malignant Parotid Tumours 1977 ·ORL ·C.‐M. Eneroth,Lars Andréasson,Miloslav Beran,A. Biörklund,Bengt Carlsöö,(unknown),Jan Olofsson,(unknown),(unknown)	14

About Miloslav Beran

Miloslav Beran is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health, having authored 106 papers that have together received 8.5k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (47 papers), Chronic Lymphocytic Leukemia Research (46 papers) and Acute Myeloid Leukemia Research (45 papers). The work is most often cited by research in Hematology (5.2k citations), Genetics (3.4k citations) and Pathology and Forensic Medicine (1.7k citations). Miloslav Beran has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include Hagop M. Kantarjian, Michael J. Keating, Charles Koller, Jörge E. Cortes, Elihu H. Estey, Francis J. Giles, Susan O’Brien, Sherry Pierce, Emil J. Freireich and Michael Andreeff. Their work appears in journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact